## PRESS INFORMATION BUREAU GOVERNMENT OF INDIA पत्र सूचना कार्यालय भारत सरकार

## The Financial Express, Delhi

Wednesday, 23rd February 2011, Page: 5

Width: 20.83 cms Height: 19.43 cms, Ref: pmin.2011-02-23.31.29

## INTERVIEW: PANCHAPAGESA MURALI

MD & CEO, EVOLVA BIOTECH

## billion with several fragmented play-Global biotech market is close to \$300 Biotech sector to grow 5 fold by 15 healthcare space. Reforms in biotech world and key player in the affordable

talks about the prospects and oppor tunities for Indian companies. director and CEO, Evolva BioTech Panchapagesa Murali, *managing* view with FE's R Ravichandran, crease to 15%. In an exclusive intersmall, but by 2020 it is expected to in in the global biotech segment is very ple. Though, at present, India's share for \$20 billion is the most recent examery pipelines of incumbent pharma has already begun due to dry discov ers. But massive consolidation drive players. Sanofitaking over Genzyme

general and India in particular? on global biotech industry in What is your overall perspective

five times more by 2015. \$3 billion and this is poised to grow drive has already commenced. From ma players, a massive consolidation biotech industry as of 2010 was about the Indian standpoint, the size of the discovery pipelines of existing pharfragmented players. But due to dry mated at \$300 billion with several The global biotech market is esti-

the industry? substantiate the growth trend of Are there any facts and figures to

contributes about 60% of the total agriculture, bio-industrial and bioma, contract research (CRAMS), biocomprises of bio-generics, bio-phar the largest vaccine producers in the revenues. Also, the country is one of At present, this segment broadly Bio-pharma

> regulations globally will enable doger more mergers & acquisitions. close to \$70 billion (from drugs comthe bio-generics market which mestic players to fiercely compete in ingoff patent)andthisislikelytotrig-

global biotech market? Where does India stand in the At present, the country's share in

the global biotech segment is very threatening diseases. tion, a large English speaking popunew drugs for treating various life the development and production of search, genetic engineering and in bioactive therapeutic, stem cell reand contract research and trials, diagnostics, gene therapy, clinical field has become an integral part in the advantages. In medicine, this plants outside the US are some of Drug Administration approved lation, largest number of Food and



CONSOLIDATION DRIVE HAS PLAYERS, A MASSIVE SEVERAL FRAGMENTED THE GLOBAL BIOTECH ALREADY COMMENCED EXISTING PHARMA DISCOVERY PIPELINES OF PLAYERS, BUT DUE TO DRY \$300 BILLION WITH MARKET IS ESTIMATED AT

small. However, due to several adopment of different agri-biotech ty. The country has one of the products applicable worldwide. that can help in research and devel world, and varied climatic zones largest agriculture sectors in the the key advantages is its bio-diversivantages, the country is likely to catapult its share to 15% by 2020. One of

tages of the sector? Heterogeneous patient popula What do you think are the advan-

Is lack of funding a concern for to invest in all the value chains (seed and life-science dedicated funds the growth of the industry? ten into services space. Thus it is imon different verticals and more ofright now, yet many of them focus perative to encourage more players Though there are several biotech

en by central and state govern-ments. Department of biotechnoloto boost the growth of the sector. There are several initiatives tak-

stage, venture stage, private equity)

Gates Foundation, TB Alliance, thropic funding avenues such as brightstart-ups. Also, many philanup their own venture capital to fund enues. State governments have set addition to several other funding av-Wellcome-DBT Trust are likely to poost innovation.

gy has BIPP and SBIRI schemes in

Can you throw light on your com tern and future plans? pany, including its growth pat-

tion with Rocheon novel cancer and anti-infective targets; with Inter-Dengue and Malaria. Evolva's mol drug pipeline has relevance to a recently announced our collaboraoped countries like the US. This in a tionhere.Sincetherearenoplayers in India in the synthetic biology ecules have tremendous applica ers in each of the domains. Evolva' not occur presently. The company's pathways and organisms that does ogy is all about creation of artificial versified applications in many avsynthetic biology company with di tions ahead of the curve. We have has to come only from very devel segment, a lot of the competition area from TB to Onychomychosis to this region. This includes a broad enues that can improve human national Flavours and Fragrances way puts Evolva's Indian opera number of diseases prevalent in innovative projects with key play pusiness model rests on partnering wellbeing. Evolva's Synthetic biol Evolva Biotech is a cutting edge

holus by.